



TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 7 March, 2024

In compliance with the reporting requirements provided for in article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, Laboratorios Farmacéuticos ROVI, S.A. (hereon, "**ROVI**" or the "**Company**") hereby discloses to the Spanish National Securities Market Commission the following

OTHER RELEVANT INFORMATION

ROVI notes the recent press speculation regarding a potential corporate transaction involving its third party contract development and manufacturing business, and hereby informs that:

ROVI regularly assesses potential strategic alternatives to maximize value. As part of the strategic review process, ROVI has engaged Lazard Asesores Financieros, S.A. It is important to note that the analysis is not concluded and there is no specific decision taken nor information to report in this regard. Any relevant decision which could eventually be taken on the matter would be disclosed to the market in accordance with applicable regulations.

Mr Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.